Show simple item record

dc.contributor.authorLeonard, Brian
dc.contributor.authorTaylor, David
dc.date.accessioned2011-01-27T14:00:23Z
dc.date.available2011-01-27T14:00:23Z
dc.date.issued2010-08
dc.identifier.citationEscitalopram--translating molecular properties into clinical benefit: reviewing the evidence in major depression. 2010, 24 (8):1143-52 J. Psychopharmacol. (Oxford)en
dc.identifier.issn1461-7285
dc.identifier.pmid20147575
dc.identifier.doi10.1177/0269881109349835
dc.identifier.urihttp://hdl.handle.net/10147/120517
dc.description.abstractThe majority of currently marketed drugs contain a mixture of enantiomers; however, recent evidence suggests that individual enantiomers can have pharmacological properties that differ importantly from enantiomer mixtures. Escitalopram, the S-enantiomer of citalopram, displays markedly different pharmacological activity to the R-enantiomer. This review aims to evaluate whether these differences confer any significant clinical advantage for escitalopram over either citalopram or other frequently used antidepressants. Searches were conducted using PubMed and EMBASE (up to January 2009). Abstracts of the retrieved studies were reviewed independently by both authors for inclusion. Only those studies relating to depression or major depressive disorder were included. The search identified over 250 citations, of which 21 studies and 18 pooled or meta-analyses studies were deemed suitable for inclusion. These studies reveal that escitalopram has some efficacy advantage over citalopram and paroxetine, but no consistent advantage over other selective serotonin reuptake inhibitors. Escitalopram has at least comparable efficacy to available serotonin-norepinephrine reuptake inhibitors, venlafaxine XR and duloxetine, and may offer some tolerability advantages over these agents. This review suggests that the mechanistic advantages of escitalopram over citalopram translate into clinical efficacy advantages. Escitalopram may have a favourable benefit-risk ratio compared with citalopram and possibly with several other antidepressant agents.
dc.language.isoenen
dc.subject.meshCitalopram
dc.subject.meshDepressive Disorder, Major
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshMale
dc.subject.meshMeta-Analysis as Topic
dc.subject.meshMolecular Conformation
dc.subject.meshPubMed
dc.subject.meshRandomized Controlled Trials as Topic
dc.subject.meshSerotonin Uptake Inhibitors
dc.subject.meshStereoisomerism
dc.subject.meshTreatment Outcome
dc.titleEscitalopram--translating molecular properties into clinical benefit: reviewing the evidence in major depression.en
dc.typeArticleen
dc.contributor.departmentDepartment of Pharmacology, National University of Ireland, Galway, Ireland.en
dc.identifier.journalJournal of psychopharmacology (Oxford, England)en
refterms.dateFOA2018-08-22T10:33:10Z
html.description.abstractThe majority of currently marketed drugs contain a mixture of enantiomers; however, recent evidence suggests that individual enantiomers can have pharmacological properties that differ importantly from enantiomer mixtures. Escitalopram, the S-enantiomer of citalopram, displays markedly different pharmacological activity to the R-enantiomer. This review aims to evaluate whether these differences confer any significant clinical advantage for escitalopram over either citalopram or other frequently used antidepressants. Searches were conducted using PubMed and EMBASE (up to January 2009). Abstracts of the retrieved studies were reviewed independently by both authors for inclusion. Only those studies relating to depression or major depressive disorder were included. The search identified over 250 citations, of which 21 studies and 18 pooled or meta-analyses studies were deemed suitable for inclusion. These studies reveal that escitalopram has some efficacy advantage over citalopram and paroxetine, but no consistent advantage over other selective serotonin reuptake inhibitors. Escitalopram has at least comparable efficacy to available serotonin-norepinephrine reuptake inhibitors, venlafaxine XR and duloxetine, and may offer some tolerability advantages over these agents. This review suggests that the mechanistic advantages of escitalopram over citalopram translate into clinical efficacy advantages. Escitalopram may have a favourable benefit-risk ratio compared with citalopram and possibly with several other antidepressant agents.


Files in this item

Thumbnail
Name:
20147575.pdf
Size:
178.5Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record